Muhunthan Thillai

Muhunthan Thillai

Qureight

---

Dr. Muhunthan Thillai is the co-founder and CEO of Qureight, a techbio company in Cambridge UK with a mission to be the data platform for lung and heart disease. The company works with biopharma, hospitals and clinical trial partners to structure imaging and clinical data in specific diseases and build ML products to add value to clinical trials by speeding them up, discovering new endpoints and helping biopharma understand the mechanisms of their drugs. It has a number of large and small biopharma partners world wide and has integrated the platform with leading Clinical Research Organisations (CROs) to work on live clinical trials. Qureight’s main disease focuses at the moment are lung fibrosis, lung cancer and pulmonary hypertension. Dr. Thillai is also a consultant chest physician at Royal Papworth Hospital and Associate Professor at the University of East Anglia. In addition to his medical degree he holds a PhD in Immunology from Imperial College London. His research interests are in lung fibrosis and he is editor of the 2019 Handbook in Interstitial Lung Diseases and co-chair of the 2020 British Thoracic Society guidelines in sarcoidosis.